[DOI] [PubMed] [Google Scholar] 84.Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, Madsen OD, Serup P, Heimberg H, Mansouri A
Journal of Autism & Developmental Disorders
A few, PT-141 among them, can be nasal
Highlights: FDA approves oral semaglutide as the first GLP-1 pill for weight loss Once-daily tablet offers comparable results to injectable Wegovy Also reduces the risk of major cardiovascular events early January 2026 (1 Trusted Source Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight management Go to source)
Perhaps oral semaglutide is not an ideal mode of delivery to achieve measurable improvements in cognitive outcomes, and another variant of GLP-1 medication would be better suited
A health professional will interpret / advise on the results